What Does a Lesion on Your Kidney Mean?

A kidney lesion is any abnormal area of tissue on or in a kidney, and the term covers everything from a harmless fluid-filled cyst to a cancerous tumor. The vast majority turn out to be benign. In one large study of patients who had CT scans for unrelated reasons, about one in seven had at least one kidney mass, and roughly 87% of those were classified as benign on imaging alone. Still, because a small fraction of kidney lesions are cancerous or need monitoring, learning what yours is and what to do about it matters.

How Most Kidney Lesions Are Discovered

Most people never feel a kidney lesion. The kidneys sit deep in the back of the abdomen, cushioned by fat, so even a sizable growth can go unnoticed for years. The vast majority of kidney lesions are found incidentally, meaning a doctor spots them on a scan ordered for something else entirely, like abdominal pain, a car accident workup, or a routine check for another condition. In a study of roughly 3,000 patients who had unenhanced CT scans for non-kidney reasons, at least one kidney mass showed up in about 14% of them, with an average size of around 25 mm.¹ That high rate speaks to how common benign kidney growths are, especially as people age.

When a lesion does cause symptoms, the classic warning signs include blood in the urine, a dull ache in the flank, or sometimes a palpable lump in the side. But these symptoms tend to show up only with larger or more advanced lesions. The incidental discovery pattern is actually good news in a way: catching a lesion early, even by accident, gives doctors the widest range of options.

The Most Common Types of Kidney Lesions

The word “lesion” sounds alarming, but it is deliberately vague. Radiologists use it because, on a scan, they can often tell that something is there without being certain what it is. Here are the broad categories:

• Simple cysts: By far the most common kidney lesion. These thin-walled, fluid-filled sacs become increasingly common with age and almost never cause problems or require treatment. They are not precancerous.
• Complex cysts: Cysts that have thicker walls, internal dividers (called septa), calcifications, or solid components. These need closer evaluation because a small percentage harbor cancer cells.
• Benign solid tumors: Angiomyolipomas (made of fat, smooth muscle, and blood vessels) and oncocytomas are the two most common. Telling them apart from kidney cancer on imaging alone can be tricky, though angiomyolipomas often contain visible fat that shows up distinctly on CT.²
• Non-neoplastic pseudotumors: Infections, inflammatory conditions like sarcoidosis or IgG4-related disease, and even amyloid deposits can form masses that look like tumors on imaging but are not true growths at all.³
• Vascular lesions: Aneurysms, arteriovenous malformations, and fistulas in the kidney’s blood vessels are rare and often symptom-free. They can be congenital or develop after trauma or medical procedures.⁴
• Malignant tumors: Renal cell carcinoma (RCC) accounts for the large majority of kidney cancers. Clear cell RCC is the most common subtype, followed by papillary and chromophobe variants.⁵

Because a scan alone cannot always distinguish between these categories, follow-up imaging, scoring systems, and sometimes biopsy are used to figure out what a lesion actually is.

How Cystic Lesions Are Scored

For cystic kidney lesions specifically, radiologists have used the Bosniak classification system for more than 30 years to estimate the chance that a cyst is cancerous.⁶ The system sorts cysts into categories based on what they look like on contrast-enhanced CT or MRI, and each category carries a different risk of malignancy.

At the low end, Bosniak I and II cysts have very low cancer rates, pooled at roughly 3% and 6% respectively in a large meta-analysis. Bosniak IIF (the “F” stands for follow-up) comes in around 7%. These three categories are generally managed with monitoring alone. The risk jumps sharply at Bosniak III, where about 55% of lesions turn out to be malignant, and Bosniak IV lesions are cancerous around 91% of the time.⁷ Bosniak III and IV cysts usually prompt surgery or another intervention.

The system was updated in 2019 to improve consistency among radiologists and to better reflect what modern imaging can show.⁸ If your radiology report mentions a Bosniak score, the number alone gives your doctor a reasonable first estimate of how worried to be.

Imaging Tools and When Biopsy Enters the Picture

CT with contrast dye is the workhorse for evaluating kidney lesions. It can show whether a mass enhances (takes up the contrast), which is one of the strongest clues that a lesion is solid and potentially cancerous rather than a simple cyst. MRI performs similarly and is especially useful when CT is inconclusive or when a patient cannot receive iodine-based contrast. In a head-to-head comparison, MRI and CT agreed on cyst classification about 94% of the time.⁹

Contrast-enhanced ultrasound (CEUS) is gaining popularity as a radiation-free alternative. It is highly sensitive, meaning it rarely misses something that CT would catch. The trade-off is lower specificity: CEUS tends to upgrade lesions to a higher Bosniak category more often than CT or MRI, which can lead to unnecessary worry or procedures.¹⁰ Your doctor might order CEUS as a first look or as follow-up for a borderline finding, but CT or MRI usually has the final say.

When imaging cannot settle the question, a percutaneous biopsy, where a needle is guided through the skin into the lesion under imaging guidance, can provide a tissue sample. This used to be controversial because of concerns about complications and the risk of spreading tumor cells along the needle track. Modern evidence is reassuring: a meta-analysis found an overall complication rate of about 3%, with serious complications in less than 1% of cases and a pooled tumor-seeding rate of effectively zero.¹¹ Another study placed the rate of minor complications at about 9%, with no major events.¹² Biopsy results can sometimes change the entire management plan, ruling out cancer and sparing you from surgery you did not need.

Risk Factors That Make a Malignant Lesion More Likely

Not every kidney lesion is random bad luck. Certain factors raise your odds of developing renal cell carcinoma specifically. The three best-established modifiable risk factors are cigarette smoking, obesity, and high blood pressure.¹³ Smoking has a direct association with both higher incidence and higher RCC-related death, though researchers are still working out the exact biological pathways.¹⁴ Obesity raises the risk of developing RCC, yet in a counterintuitive twist sometimes called the “obesity paradox,” obese patients who do develop kidney cancer tend to have somewhat better survival outcomes than thinner patients.

People on long-term dialysis develop a condition called acquired cystic kidney disease, where numerous cysts form in their shrunken kidneys, and this substantially increases the risk of kidney cancer.¹⁵ Diets rich in fruits and vegetables may offer some protection, though evidence on diet and physical activity remains mixed.

On the genetic side, two hereditary conditions are particularly worth knowing about. Von Hippel-Lindau (VHL) disease, caused by a mutation in the VHL tumor-suppressor gene, predisposes people to recurrent and bilateral kidney cysts that can progress to clear cell RCC.¹⁶ Tuberous sclerosis complex (TSC) is another genetic condition that frequently affects the kidneys, most commonly causing angiomyolipomas and renal cysts.¹⁷ If you have a family history of either syndrome, your doctor will likely recommend regular kidney imaging even if you feel fine.

When Watching and Waiting Is the Right Move

Not every suspicious kidney lesion needs to be cut out immediately. For small renal masses, defined as enhancing lesions under 4 cm, active surveillance with regular imaging is now recognized as a safe, guideline-endorsed strategy. These small tumors grow slowly, and the risk of them spreading is extremely low.¹⁸ Active surveillance is particularly appealing for older patients or those with other serious health conditions, because the risks of surgery might outweigh the risks of a slow-growing tumor.

Research increasingly supports active surveillance as acceptable for tumors up to 4 cm and even as a preferred initial approach for many tumors under 2 cm. For younger patients, surveillance appears oncologically safe in the short and medium term, though whether it can indefinitely avoid intervention remains unclear.¹⁹ During surveillance, your doctor will track things like growth rate, the tumor’s longest diameter, biopsy results if one was done, whether the tumor has grown into surrounding structures, and whether you are experiencing symptoms. These criteria, sometimes grouped under the acronym GLASS, help guide the decision about when to intervene.

Active surveillance does not mean ignoring the lesion. It means checking it on a set schedule, typically with imaging every few months initially, then less frequently if the mass stays stable. If the tumor starts growing faster or crossing size thresholds, the plan shifts toward treatment.²⁰

Surgery, Ablation, and How They Compare

When treatment is needed, partial nephrectomy, where the surgeon removes the tumor while leaving the rest of the kidney intact, is considered the preferred approach for most localized kidney cancers. Preserving kidney tissue matters because it reduces the long-term risk of chronic kidney disease. In a study tracking patients after radical nephrectomy (removal of the entire kidney), roughly 43% developed chronic kidney disease within five years, with older age and lower baseline kidney function being the strongest predictors.²¹ Partial nephrectomy sidesteps much of that risk by keeping the healthy portion of the kidney working.

Thermal ablation, which destroys the tumor with extreme heat (radiofrequency ablation) or cold (cryoablation) through a needle, is another option. For small tumors up to about 4 cm (stage cT1a), ablation shows comparable long-term cancer control to partial nephrectomy in meta-analyses, with radiofrequency ablation in particular performing well.²² The picture changes for larger tumors (cT1b, roughly 4 to 7 cm), where partial nephrectomy has a meaningfully lower local recurrence rate compared to ablation.²³

Among ablation techniques, cryoablation may have an edge over radiofrequency ablation when it comes to preventing distant spread. One large cohort study found that metastasis-free survival was similar between partial nephrectomy and cryoablation, but worse for radiofrequency ablation in smaller tumors.²⁴ For patients who are poor surgical candidates because of age, frailty, or other medical conditions, percutaneous ablation offers a minimally invasive path that still achieves solid cancer control for well-selected small tumors.

Making the Decision Together With Your Doctor

Choosing between surveillance, surgery, and ablation involves weighing your overall health, the characteristics of the lesion, your personal priorities, and the likely trajectory. Research on patients with localized kidney cancer has found a significant gap between what shared decision-making should look like and what actually happens in clinic.²⁵ Patients consistently express a desire to be more involved in these decisions, yet many feel the conversation is too rushed or too one-sided.

If you are told you have a kidney lesion, a few questions can help ground the conversation: What does the imaging suggest this is? What is my Bosniak or size category? Would a biopsy change the plan? Am I a candidate for active surveillance? And if treatment is needed, which approach best preserves my kidney function? The psychological weight of hearing “lesion” or “mass” is real. A study of patients with kidney cancer found average distress scores close to the clinical threshold for needing psychological support, regardless of tumor stage or prognosis.²⁶ Feeling distressed after this kind of news is normal, and it does not mean your situation is dire.

Unusual Ways Kidney Tumors Can Announce Themselves

Kidney cancer has an unusual tendency to affect the rest of the body even before it has spread. Close to a third of patients with RCC develop what are called paraneoplastic syndromes, where the tumor produces hormones or other substances that trigger symptoms far from the kidney itself.²⁷ These can include unexplained fevers, weight loss, abnormally high calcium levels, or liver function abnormalities in a liver that has no cancer in it. In some cases, dangerously high calcium is the very first sign that leads to the discovery of a kidney tumor.²⁸

The reassuring part is that having a paraneoplastic syndrome does not automatically mean the cancer has spread, nor does it necessarily mean the outlook is poor. These symptoms often resolve once the tumor is removed. But they do make kidney cancer one of the trickier cancers to recognize clinically, because a patient might first show up at an endocrinologist’s office for a calcium problem or at an internist’s office for unexplained fevers before anyone thinks to image the kidneys.

Artificial Intelligence in Kidney Lesion Diagnosis

One area of active development is the use of deep learning models to analyze kidney CT scans. A recent study published in Nature Communications showed that an AI-based diagnostic model outperformed both traditional scoring systems and radiomics-based models at predicting whether a kidney mass was malignant, and it could do so across multiple CT scan phases.²⁹ The model could also link imaging features to pathologic characteristics and survival outcomes, which could eventually help doctors tailor treatment plans before a patient even reaches the operating room.

These tools are not replacing radiologists. They are being developed as a second set of eyes, particularly useful for the lesions that fall into gray zones on imaging, like a Bosniak IIF cyst or a small solid mass that could be either an oncocytoma or an early cancer. If validated in larger clinical trials, AI-assisted imaging could reduce the number of unnecessary biopsies and surgeries while catching more of the lesions that genuinely need attention.